Adapting cold chain and fill-finish capabilities for new drug modalities

Jeong Jin-hyeok, associated director of Aseptic Filling, at Samsung Biologics, examines the lessons learned following the onset of COVID-19 and highlights how CDMO flexibility is helping to hail in an era of new therapeutic modalities.